疫苗相关疾病增强(VADE):对COVID-19疫苗接种后的考虑

IF 0.8 Q3 MEDICINE, GENERAL & INTERNAL Case Reports in Medicine Pub Date : 2021-10-29 eCollection Date: 2021-01-01 DOI:10.1155/2021/9673453
Rahajeng N Tunjungputri, Erpryta Nurdia Tetrasiwi, Merlinda Veronica, Jacub Pandelaki, Fera Ibrahim, Erni Juwita Nelwan
{"title":"疫苗相关疾病增强(VADE):对COVID-19疫苗接种后的考虑","authors":"Rahajeng N Tunjungputri,&nbsp;Erpryta Nurdia Tetrasiwi,&nbsp;Merlinda Veronica,&nbsp;Jacub Pandelaki,&nbsp;Fera Ibrahim,&nbsp;Erni Juwita Nelwan","doi":"10.1155/2021/9673453","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. <i>Case Illustration</i>. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake.</p><p><strong>Conclusion: </strong>We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination.</p>","PeriodicalId":9627,"journal":{"name":"Case Reports in Medicine","volume":"2021 ","pages":"9673453"},"PeriodicalIF":0.8000,"publicationDate":"2021-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570879/pdf/","citationCount":"8","resultStr":"{\"title\":\"Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19.\",\"authors\":\"Rahajeng N Tunjungputri,&nbsp;Erpryta Nurdia Tetrasiwi,&nbsp;Merlinda Veronica,&nbsp;Jacub Pandelaki,&nbsp;Fera Ibrahim,&nbsp;Erni Juwita Nelwan\",\"doi\":\"10.1155/2021/9673453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. <i>Case Illustration</i>. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake.</p><p><strong>Conclusion: </strong>We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination.</p>\",\"PeriodicalId\":9627,\"journal\":{\"name\":\"Case Reports in Medicine\",\"volume\":\"2021 \",\"pages\":\"9673453\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2021-10-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570879/pdf/\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/9673453\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/9673453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 8

摘要

导言:COVID-19大流行已进入一个新阶段,全球正在加速推出几种疫苗。接种疫苗后出现更严重的COVID-19症状可能会影响决策者的决策和公众对疫苗的吸收。疫苗相关疾病增强(VADE)是个体在先前接种疫苗后感染的修改表现。目前,对COVID-19免疫接种后疫苗相关疾病增强(VADE)的潜力知之甚少。例说明。我们在此报告两例确诊为COVID-19肺炎并有冠状病毒疫苗接种史的住院患者。病程相对较轻的第一名患者接受了两剂CoronaVac,而病程较严重的第二名患者在出现症状并入院之前只接受了一剂。我们的观察结果表明,疫苗接种可以促进炎症过程,并揭示之前无症状的COVID-19疾病。理论上,疫苗可以诱导VADE,其中只产生次优的,非保护性滴度的中和抗体或诱导促炎性t辅助型2反应。其次,可能表现为增强呼吸系统疾病(ERD),由于支气管周围单核细胞和嗜酸性粒细胞浸润,肺部症状更为严重。了解VADE对于公众、临床医生和政策制定者的决策非常重要,并且是成功接种疫苗的保证。结论:我们报告了两例在冠状病毒疫苗接种后不久发生COVID-19的患者,其中有可能发生VADE。我们建议当前的疫苗接种策略考虑将中和抗体滴度的测量作为确保最安全的大规模免疫策略的指导。需要进行研究,以调查接种疫苗个体中VADE的真实发病率,以及如何区分VADE与与疫苗接种无关的COVID-19严重表现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19.

Introduction: The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake.

Conclusion: We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Case Reports in Medicine
Case Reports in Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
1.70
自引率
0.00%
发文量
53
审稿时长
13 weeks
期刊最新文献
Honey as an Alternative Dressing in Post-Palatoplasty-Two Case Reports. Renal Cell Carcinoma Masquerading as Acute Upper Gastrointestinal Bleeding. Case of T-B+NK+ X-Linked Severe Combined Immunodeficiency Disease. Case Study: Analyzing CFTR Mutations and SNPs in Pulmonary Fibrosis Patients with Unclear Symptoms. Tuberculosis Meningitis in a 9-Month-Old Girl during the COVID-19 Pandemic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1